Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair (GZTR) -- Ignore unavailable to you. Want to Upgrade?

To: Linda Kaplan who wrote (1970)	7/12/1998 10:41:00 PM
From: ajs	Read Replies (1) \| Respond to of 2553

Interesting article in this months "Worth" magazine regarding the inefective drugs currently on the market for ulcers & heartburn, basically current drugs, "Tagement, Zantac" are huge sellers but only treat the symptoms. - Genzl was not mentioned but if they can develop a successful new treatment the market will huge, 40% of the population will suffer from heartburn at some point in there lives.

To: Linda Kaplan who wrote (1970)	7/13/1998 11:32:00 AM
From: Machaon	Respond to of 2553

Hi Linda. Congratulations, again, on your excellent timing. I wouldn't mind picking up some more GENZL, at the price that you paid. Epicel is GENZL's skin product, for burns, that they grow from a piece of a burn victim's own skin. It was their first commercial product. Up to now, it hasn't seen much growth. I am hoping that the reduced turnaround, to 16 days, will cause Epicel to become a growth product. This AIM system sounds interesting. Sounds like it really works for you. Good luck, Bob